Champions Oncology, Inc.
CSBR · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | -0.23 | 0.01 | 3.67 |
| FCF Yield | 7.16% | -10.61% | 1.65% | 4.06% |
| EV / EBITDA | 14.49 | -13.95 | -31.07 | 45.57 |
| Quality | ||||
| ROIC | 46.44% | -123.55% | -30.05% | 3.01% |
| Gross Margin | 50.15% | 41.38% | 45.18% | 51.88% |
| Cash Conversion Ratio | 1.57 | 0.84 | -0.74 | 11.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.87% | 0.71% | 9.49% | 15.20% |
| Free Cash Flow Growth | 200.34% | -743.86% | -73.67% | 182.89% |
| Safety | ||||
| Net Debt / EBITDA | -0.57 | -0.95 | 0.73 | 0.21 |
| Interest Coverage | 168.63 | 0.00 | 0.00 | 25.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 17.39 | -2.68 | -11.65 | 26.41 |